<DOC>
	<DOCNO>NCT00112021</DOCNO>
	<brief_summary>This study examine effect pramlintide body weight safety tolerability obese subject .</brief_summary>
	<brief_title>A Study Examine Effect Pramlintide Body Weight Its Safety Tolerability Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Is obese body mass index ( BMI ) &gt; =30 kg/m^2 &lt; =50 kg/m^2 , obese least one year screening . Usually consume least three major meal ( morning , midday , even ) day . Is currently enrol formal weightloss program . Has liposuction within 1 year screen plan liposuction study . Has receive investigational drug within 3 month screen . Has previously participate study use pramlintide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>obesity</keyword>
	<keyword>weight loss</keyword>
	<keyword>Amylin</keyword>
	<keyword>pramlintide</keyword>
	<keyword>Symlin</keyword>
</DOC>